News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Conference News ACC 2020 Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients L.A. McKeown April 01, 2020